| Literature DB >> 34899638 |
Peng Zhang1, Jiali Fang1, Guanghui Li1, Lei Zhang1, Xingqiang Lai1, Lu Xu1, Luhao Liu1, Yunyi Xiong1, Li Li1, Tao Zhang1, Jiao Wan1, Hailin Xu1, Rongxin Chen1, Weiting Zhang1, Junjie Ma1, Zheng Chen1.
Abstract
This study investigated the sex-specific differences in the correlation between intestinal microbiota and end-stage renal disease. Here, we compared the differences in the gut microbiota of male and female healthy controls (HC) and patients with end-stage renal disease (ESRD) caused by immunoglobulin A (IgA) nephropathy (ESRD-IgAN) or type-2 diabetes mellitus (ESRD-T2DM) using high-throughput sequencing of the 16S rRNA gene. We also analyzed the correlation between gut microbiota and clinical immune indicators. We assigned 8, 10, 5, 7, 11, and 20 volunteers to female HC, ESRD-IgAN, and ESRD-T2DM, and male HC, ESRD-IgAN, and ESRD-T2DM, respectively. The results showed sex-specific differences in both physiological and biochemical indices and intestinal microbiota composition, as well as the correlation between them. The correlations between physiological and biochemical indices in men were significantly lower than those in women, especially for indices related to immunity, blood glucose, and cardiac color sonography. Urine output, lymphocyte ratio, serum albumin, blood calcium, dialysis status, serum urea nitrogen, urine protein, and diabetes significantly correlated with male fecal microbiota composition, whereas only creatinine and 2-h post-prandial blood glucose significantly correlated with female fecal microbiota composition. The top 50 dominant operational taxonomic units showed a stronger correlation with physiological and biochemical indices in samples obtained from females than from males. These differences highlight sex-specific differences in the effectiveness of ESRD prevention and treatments via regulating intestinal microbiota.Entities:
Keywords: IgA nephropathy; chronic kidney disease; clinical immune indicators; end-stage renal disease; gut microbiota; type-2 diabetes mellitus
Year: 2021 PMID: 34899638 PMCID: PMC8661007 DOI: 10.3389/fmicb.2021.752393
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
General characteristics, and physiological and biochemical indices of blood and urine of volunteers.
| Item | FHC | FESRD-IgAN | FESRD-T2DM | MHC | MESRD-IgAN | MESRD-T2DM |
| Sample size | 8 | 10 | 5 | 7 | 11 | 20 |
| Age | 48.63 ± 3.52 | 47.60 ± 2.90 | 52.60 ± 3.49 | 39.86 ± 2.87 | 42.10 ± 3.21 | 48.35 ± 1.93 |
| Height (cm) | 156.0 ± 1.80 | 158.1 ± 2.10 | 160.8 ± 1.50ab | 172.7 ± 1.86 | 171.3 ± 1.73 | 170.5 ± 1.17 |
| Weight (kg) | 54.91 ± 2.43 | 52.84 ± 3.48 | 53.60 ± 4.93 | 73.81 ± 1.88 | 67.85 ± 3.73 | 71.41 ± 2.54 |
| BMI | 22.56 ± 0.88 | 20.95 ± 0.89 | 20.70 ± 1.81 | 24.80 ± 0.83 | 23.06 ± 1.08 | 24.50 ± 0.73 |
|
| 1901.9 ± 208.1 | 905.0 ± 204.1 | 1488.0 ± 156.9 | 1941.4 ± 69.7 |
|
|
| FBG (mmol/L) | 4.53 ± 0.14 | 3.92 ± 0.45 | 4.96 ± 0.57 | 4.72 ± 0.21 | 4.34 ± 0.35 | 5.44 ± 0.46 |
|
|
| 10.37 ± 0.56 |
| 9.65 ± 0.60 | 8.80 ± 0.78 | 10.97 ± 0.50 |
|
|
| 9.31 ± 1.07 |
| 6.95 ± 0.79 | 8.54 ± 0.40 | 11.10 ± 0.75 |
|
| 5.56 ± 0.05 | 5.46 ± 0.08 | 5.86 ± 0.33 |
| 5.30 ± 0.15 |
|
|
| 3.44 ± 0.32 | 6.37 ± 0.75 | 6.26 ± 0.74 |
| 8.03 ± 1.13 |
|
| SCPO (ng/mL) | 11.26 ± 1.12 | 15.83 ± 2.43 | 12.62 ± 2.51 | 12.00 ± 0.72 | 16.11 ± 1.93 | 12.86 ± 1.61 |
| SCPT (ng/mL) | 12.46 ± 1.33 | 21.94 ± 4.03 | 16.09 ± 4.40 | 14.49 ± 1.67 | 20.01 ± 2.89 | 14.73 ± 1.96 |
|
| 72.61 ± 3.14 | 606.92 ± 116.06 | 769.56 ± 87.52 |
|
|
|
|
|
|
|
|
|
|
|
| Uric acid (μmol/L) | 467.50 ± 144.84 | 366.90 ± 42.16 | 423.40 ± 69.45 | 361.29 ± 19.37 | 493.70 ± 47.03 | 445.95 ± 27.59 |
| While blood cell (10 | 5.86 ± 0.45 | 6.70 ± 0.54 | 6.72 ± 0.41 | 6.73 ± 0.65 | 7.05 ± 0.40 | 7.45 ± 0.38 |
|
|
|
| 67.16 ± 2.09 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 135.57 ± 5.59 | 102.70 ± 4.97 | 106.20 ± 4.38 |
| RBCC (1012/L) | 4.16 ± 0.10 | 3.50 ± 0.25 | 3.31 ± 0.46 | 4.64 ± 0.41 | 3.38 ± 0.14 | 3.63 ± 0.15 |
| Platelet (10 | 238.50 ± 33.73 | 251.60 ± 28.63 | 185.00 ± 27.74 | 254.43 ± 29.09 | 178.70 ± 16.35 | 210.45 ± 13.00 |
|
| 2.13 ± 0.23 | 2.34 ± 0.06 | 2.31 ± 0.06 |
| 2.23 ± 0.05 |
|
| Blood phosphorus (mmol/L) | 6.14 ± 2.28 | 1.97 ± 0.28 | 1.83 ± 0.26 | 2.55 ± 1.27 | 1.80 ± 0.16 | 2.06 ± 0.13 |
| Troponin (ng/mL) | 1.17 ± 0.75 | 4.63 ± 1.70 | 3.48 ± 1.54 | 1.06 ± 1.04 | 3.22 ± 1.80 | 52.52 ± 48.92 |
|
| 40.05 ± 1.36 | 38.75 ± 1.88 | 35.32 ± 1.22 |
|
|
|
|
| 11.84 ± 1.36 | 11.94 ± 4.03 | 16.64 ± 4.64 |
| 10.28 ± 1.67 |
|
|
| 17.59 ± 0.76 | 14.41 ± 2.10 | 20.28 ± 3.95 |
|
|
|
| Urine leukocytes (U/L) | 9.83 ± 3.44 | 10.67 ± 3.98 | 5.00 ± 1.50 | 13.24 ± 8.49 | 22.74 ± 16.29 | 226.92 ± 155.21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| CD3+ (%) | 75.81 ± 0.69 | 79.68 ± 1.88 | 83.42 ± 1.62 | 75.50 ± 0.58 | 76.77 ± 2.27 | 78.51 ± 1.54 |
| CD3 + CD4 + (%) | 43.70 ± 0.75 | 47.21 ± 2.97 | 55.70 ± 5.06 | 45.57 ± 1.22 | 42.36 ± 2.38 | 44.90 ± 1.82 |
| CD3 + CD8+ (%) | 34.58 ± 0.87 | 28.53 ± 2.21 | 24.68 ± 4.55 | 35.56 ± 0.69 | 29.67 ± 2.33 | 28.93 ± 1.55 |
| CD19+ (%) | 10.26 ± 0.13 | 8.29 ± 1.13 | 7.10 ± 1.79 | 10.74 ± 0.42 | 11.14 ± 1.51 | 8.64 ± 0.87 |
|
|
|
|
| 16.56 ± 0.52 | 10.08 ± 2.22 | 10.74 ± 1.63 |
| C3 (g/L) | 0.95 ± 0.02 | 0.69 ± 0.03 | 0.71 ± 0.04 | 0.95 ± 0.02 | 0.81 ± 0.07 | 2.14 ± 1.30 |
| C4 (g/L) | 0.21 ± 0.01 | 0.19 ± 0.01 | 0.20 ± 0.01 | 0.24 ± 0.01 | 0.19 ± 0.01 | 0.24 ± 0.01 |
| IgA (g/L) | 2.28 ± 0.15 | 2.80 ± 0.31 | 2.86 ± 0.57 | 2.86 ± 0.20 | 2.15 ± 0.20 | 2.18 ± 0.24 |
| IgG (g/L) | 13.04 ± 0.51 | 14.99 ± 1.07 | 12.87 ± 1.67 | 13.06 ± 0.30 | 11.02 ± 1.14 | 11.19 ± 0.65 |
|
| 1.33 ± 0.14 | 1.01 ± 0.08 | 1.20 ± 0.40 |
|
|
|
| EF (%) | 64.38 ± 1.38 | 67.90 ± 1.49 | 70.00 ± 1.97 | 62.00 ± 1.35 | 64.55 ± 2.83 | 60.95 ± 2.24 |
| FS (%) | 35.13 ± 1.14 | 38.30 ± 1.17 | 39.40 ± 1.63 | 36.14 ± 1.28 | 35.45 ± 2.04 | 33.05 ± 1.46 |
Data are expressed as mean ± standard error of mean (SEM).FHC, FESRD-IgAN, and FESRD-T2DM indicate female healthy control and patients with end-stage renal disease caused by IgA nephropathy (ESRD-IgAN) or type-2 diabetes mellitus (ESRD-T2DM), respectively. MHC, MESRD-IgAN, and MESRD-T2DM indicate male healthy control and patients with ESRD-IgAN, or ESRD-T2DM, respectively. BMI, body mass index; FBG, fasting blood glucose; OPBG, one-hour post-prandial blood glucose; TPBG, two hours post-prandial blood glucose; FSCP, fasting serum C-peptide; SCPO, serum C-peptide one hour after meal; SCPT, serum C-peptide two hours after meal; RBCC, red blood cell count. NK, nature killer cell; C3, complement 3; C4, complement 4; IgA, immunoglobulin A; IgG, immunoglobulin G; IgM, immunoglobulin M; EF, ejection fraction; FS, fractional shortening. Different lowercases at the upper right of the mean ± standard error showed the statistical significance (p < 0.05).
The bold values indicate the indices that showed significant changes in male and female volunteers.
FIGURE 1Co-occurrence networks of (A) male and (B) female physiological and biochemical indices. Nodes indicate the physiological and biochemical indices. Edge width indicates the Pearson correlation. Red and blue edges indicate significantly positive (Pearson correlation coefficient > 0.6 and P < 0.05) and significantly negative correlations (Pearson correlation index < −0.6 and P < 0.05). BMI, body mass index; NK, nature killer cell; C3, complement 3; IgA, immunoglobulin A; IgG, immunoglobulin G; EF, ejection fraction; FS, fractional shortening.
FIGURE 2(A) Dominant phyla in the fecal microbiota of healthy controls and patients with end-stage renal disease caused by IgA nephropathy or type-2 diabetes mellitus. PCoA profiles based on (B) unweighted and (C) weighted UniFrac distances of OTU compositions showing changes in fecal microbiota. FHC, FESRD-IgAN, and FESRD-T2DM indicate female healthy control and patients with end-stage renal disease caused by IgA nephropathy (ESRD-IgAN) or type-2 diabetes mellitus (ESRD-T2DM), respectively. MHC, MESRD-IgAN, and MESRD-T2DM indicate male healthy control and patients with ESRD-IgAN, or ESRD-T2DM, respectively.
FIGURE 3(A) Heatmap and (B,C) ternary diagram profiles showing the dominant OTU differences in fecal microbiota of male and female healthy controls and patients with end-stage renal disease caused by IgA nephropathy (ESRD-IgAN) or type-2 diabetes mellitus (ESRD-T2DM). FHC, FESRD-IgAN, and FESRD-T2DM indicate female healthy control and patients with end-stage renal disease caused by IgA nephropathy (ESRD-IgAN) or type-2 diabetes mellitus (ESRD-T2DM), respectively. MHC, MESRD-IgAN, and MESRD-T2DM indicate male healthy control and patients with ESRD-IgAN, or ESRD-T2DM, respectively.
FIGURE 4Correlation between physical, blood, and urine indices of volunteers and their fecal microbiota compositions. (A,C) Tb-RDA profile showing the correlation between physical, blood, and urine indices of male and female volunteers and their fecal microbiota OTU compositions. (B,D) Bubble charts showing the Pearson correlation between physical, blood, and urine indices of male and female volunteers and the top 50 dominant OTUs in their fecal microbiota. FBG, fasting blood glucose; OPBG, one-hour post-prandial blood glucose; TPBG, two hours post-prandial blood glucose; FSCP, fasting serum C-peptide; SCPO, serum C-peptide one hour after meal; SCPT, serum C-peptide two hours after meal; RBCC, red blood cell count. *, p < 0.05; **, p < 0.01; ***, p < 0.001.